LOPROX SHAMPOO SUMMARY
LOPROX® (ciclopirox) Shampoo 1% contains the synthetic antifungal agent, ciclopirox.
LOPROX Shampoo is indicated for the topical treatment of seborrheic dermatitis of the scalp in adults.
Media Articles Related to Loprox Shampoo (Ciclopirox Shampoo)
Source: MedicineNet ciclopirox Specialty [2012.03.16]
Title: Seborrheic Dermatitis
Category: Diseases and Conditions
Created: 3/16/2012 5:47:00 PM
Last Editorial Review: 3/16/2012 5:47:54 PM
Published Studies Related to Loprox Shampoo (Ciclopirox Shampoo)
A randomized, double-blind study comparing the efficacy of selenium sulfide shampoo 1% and ciclopirox shampoo 1% as adjunctive treatments for tinea capitis in children. [2010.09]
Our objective was to compare the efficacy of selenium sulfide shampoo 1% and ciclopirox shampoo 1% as adjunctive treatments for tinea capitis in children. Forty children aged 1-11 years with clinically diagnosed tinea capitis were randomized to receive selenium sulfide shampoo 1% or ciclopirox shampoo 1% twice a week as adjuncts to an 8-week course of ultramicronized griseofulvin dosed at 10-12 mg/kg/day...
Randomized study comparing the efficacy and tolerance of a lipohydroxy acid shampoo to a ciclopiroxolamine shampoo in the treatment of scalp seborrheic dermatitis. [2009.12]
BACKGROUND: The success of a dandruff treatment depends not only on the ability of a shampoo to control dandruff, but also on patient compliance, which is closely linked to the cosmetic attributes of the product. AIM: The aim of this study was to compare efficacy, tolerance, and cosmetic properties of a LHA Shampoo [containing 0.1% lipohydroxy acid (LHA) and 1.3% salicylic acid] to a CPO shampoo [containing 1.5% ciclopiroxolamine (CPO), 3% salicylic acid, and 0.5% menthol] in subjects with seborrheic dermatitis (SD) of the scalp... CONCLUSION: In conclusion, these results demonstrated that the lipohydroxy acid shampoo evaluated in this study is a more convenient, efficient, safe, and well-tolerated cosmetic treatment for mild-to-moderate seborrheic dermatitis of the scalp than a ciclopiroxolamine shampoo.
Clinical efficacy of a new ciclopiroxolamine/zinc pyrithione shampoo in scalp seborrheic dermatitis treatment. [2006.09]
Ciclopiroxolamine (CPO) and Zinc Pirythione (ZP) antifungals are efficient at treating scalp seborrheic dermatitis.This multicentre, single-blind, clinical study was conducted to evaluate the efficacy of a shampoo containing the 1.5% CPO/1% ZP association compared to the vehicle shampoo and to 2% ketoconazole foaming gel in the treatment of seborrheic dermatitis.In 189 patients randomised to apply 1 of the 3 products twice a week for 28 days, the global lesional score, erythema, pruritus, global efficacy, quality of life (SF12 and DLQI questionnaires) and tolerance were measured at 0, 7, 14 and 28 days.The 3 products reduced lesional score, erythema and pruritus from day 7 (p < 0.0001)...
Treatment and prophylaxis of seborrheic dermatitis of the scalp with antipityrosporal 1% ciclopirox shampoo. [2005.01]
OBJECTIVE: To demonstrate the efficacy, safety, and tolerance of ciclopirox shampoo for treatment and prophylaxis of seborrheic dermatitis of the scalp... CONCLUSIONS: Seborrheic dermatitis of the scalp responds well to 1% ciclopirox shampoo once or twice weekly for 4 weeks. A low relapse rate is maintained by once-weekly shampooing or shampooing once every 2 weeks. These treatments are safe and well-tolerated.
Safety and efficacy of ciclopirox 1% shampoo for the treatment of seborrheic dermatitis of the scalp in the US population: results of a double-blind, vehicle-controlled trial. [2004.07]
BACKGROUND: Seborrheic dermatitis is a common inflammatory skin disorder. Yeasts of the genus Malassezia have been implicated in the etiology of seborrheic dermatitis, although this connection remains controversial. Ciclopirox is a synthetic, hydroxypyridone-derived, broad-spectrum antifungal agent with anti-inflammatory properties... CONCLUSIONS: Ciclopirox shampoo 1% is effective and safe in the treatment of seborrheic dermatitis of the scalp.
Clinical Trials Related to Loprox Shampoo (Ciclopirox Shampoo)
Efficacy, Safety and Cost-effectiveness of a Sequential Therapy With RV4104A Ointment, Ciclopiroxolamine Cream and Ciclopirox Film-forming Solution Compared With Amorolfine Nail Lacquer in Dermatophytic Onychomycosis [Recruiting]
The purpose of the study is to evaluate and compare the efficacy of the sequential
association RV4104A ointment followed by ciclopiroxolamine 1% cream and ciclopirox 8%
film-forming solution versus amorolfine 5% nail lacquer alone in the treatment of patients
with dermatophytic onychomycosis (toenail) without matrix involvement.
Study Evaluating the Tolerance and Biologic Activity of Oral Ciclopirox Olamine in Patients With Relapsed or Refractory Hematologic Malignancy [Recruiting]
This is an open-label, single arm study. Approximately 3-30 patients will be enrolled.
Patients will receive Oral ciclopirox olamine (aqueous suspension), initial starting dose of
5 mg/m2/day administered as a single dose daily for 5 days. Three patients will initially be
treated at each dose level in sequential cohorts. Dose escalation will continue for each
subsequent cohort based on toxicity and plasma drug concentrations observed during the
previous cohort. Dose escalation will continue until establishment of the maximum tolerated
dose (MTD) has been met.
Patients who have demonstrated response to treatment, up to 6 total cycles of treatment may
be administered. If additional cycles are warranted, ciclopirox olamine will be given at
the same dose and frequency as the patient initially received.
Chemoprevention of Cancer in the Lower Female Genital Tract: The Antineoplastic Activity of the Fungicide Ciclopirox. [Recruiting]
The purpose of this study is to determine if regular and daily repeated application of the
ciclopirox lotion to vulva will make the precancerous lesion(s) shrink or even disappear.
Selenium Sulfide, Ketoconazole and Ciclopirox Shampoo as Additional Treatments for Tinea Capitis (Scalp Ringworm) [Recruiting]
Antifungal shampoos have been used as supplements to oral griseofulvin to help eradicate
tinea capitis (also known as ringworm of the scalp) more quickly. While selenium sulfide
shampoo has been the gold standard, its strong odor and its drying effect on the scalp
discourage many patients from using it. Meanwhile, no other antifungal shampoo has been
rigorously evaluated for efficacy. Therefore, while physicians are prescribing griseofulvin
accompanied by any of a number of antifungal shampoos for tinea capitis, it is not known
which antifungal shampoos (excluding selenium sulfide) actually significantly reduce time to
cure, nor which do so the fastest.
Scalp ringworm can also re-occur in the same child. To date, no studies have been done to
find out whether or not the use of antifungal shampoos can prevent the recurrence of scalp
In this study, children ages 1-12 years old, who have clinically diagnosed tinea capitis,
will all be prescribed oral griseofulvin for 8 weeks. In addition, they will be randomly
assigned to use either selenium sulfide shampoo, ketoconazole shampoo, ciclopirox shampoo, or
baby shampoo twice a week for 8 weeks. After 8 weeks, griseofulvin will be stopped. All
patients will continue using the same assigned shampoo twice weekly for 24 weeks, while
continuing to return to clinic every 4 weeks for scalp evaluation.
Efficacy and Safety of Low-dose Oral Isotretinoin for Seborrhea [Recruiting]
Oral isotretinoin is the gold standard drug to treat moderate to severe acne. Other
indications like seborrhea, seborrheic dermatitis have been suggested. There is risk of
reversible mucocutaneous side effects, as well as alterations in lipid profile and
transaminases. The major problem is teratogenicity which demands pregnancy control from
treatment beginning to one month after treatment end. Seborrhea and seborrheic dermatitis
are chronic conditions characterized by oily skin, hair and scalp, erythema, desquamation
and negative impact on quality of life. This will be an interventional, therapeutic and
quality of life randomized, comparative (parallel groups), blinded evaluation clinical
trial, comprising 50 men and women, aged 18 to 40. Treatment with low-dose oral isotretinoin
will be compared to topical anti-seborrheic products to evaluate the reduction of sebaceous
secretion and colonization of affected areas by yeasts of Malassezia gender. Efficacy will
be evaluated by clinical parameters, as well as by sebum secretion measure and application
of quality of life questionnaires. Safety will be evaluated by skin hydration measure, side
effects report and observation. For subjects using oral isotretinoin blood counting,
transaminases, lipid profile and pregnancy test will be requested as selection criteria, on
days 30 and 180. Data will be submitted to statistical analysis.
Page last updated: 2012-03-16